Table 2.
Constituent ratio of NVTs in the era of PCV13 in some studies mentioned above
| Pre-PCV13 period |
Post-PCV13 period |
|||||
|---|---|---|---|---|---|---|
| Country | Age | Year | Non-PCV13-associated IPD | Year | Non-PCV13-associated IPD | Most prevalent serotypes |
| German15 | <16 years | - | - | 2015–2016 | 84.1% | - |
| England11,17,31 | All | 2008–2010 | 46.1% | 2015–2016 | 80.6% | 8, 12 F, 10A, and 9 N |
| Belgium21 | Adults | 2007–2010 | 31% | 2012–2015 | 49% | 12, 8, and 15 groups |
| Denmark23 | All | - | - | 2014 | 71% | - |
| 0–4 years >65 years |
- - |
- - |
2014 2014 |
91% 73% |
- - |
|
| India22 | - | 2007 | 2016 | 21% | 10 F, 9 N, 11A, 20, 15B | |
| Hokkaido26 | All | 2013 | 39.7% | 2014 | 75.1% | 15A, 23A, 11A, 10A, and 35B |
| Japan27 | - | 2012 | 51.6% | 2014 | 71.4% | 24 F and 15A |
| Hongkong28 | - | 2009–2010 | 29.4% | 2010–2013 | 56.4% | 15B, 15 C, 6 C, and 15A |
| Taiwan29 | - | 2012–2013 | 17% | 2014–2015 | 44% | 15A/F, 15B/C, and 23A |
| Balearic Islands22 | - | 2012–2015 | - | 2016–2019 | 58.7% | - |
| Beijing30 | - | 2014–2016 | 0% | 2017–2019 | 11.7% | 15A and 15B |
See text for details on local vaccine use.